Cytokine neutralization at specific cellular source : A new therapeutic paradigm?

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Current autoimmune disease treatments target general immune mechanisms, leading to side effects due to essential cytokine functions.
• Cytokines like tumor necrosis factor (TNF) and interleukin-6 (IL-6) play complex roles in immunity and disease.

Purpose of the Study:

• To investigate the distinct roles of TNF from different cell types in autoimmune diseases.
• To develop a targeted therapeutic strategy for autoimmune diseases by selectively inhibiting pathogenic TNF.

Main Methods:

• Utilized reverse genetics and conditional gene targeting to study cytokine functions.
• Designed and tested a myeloid-specific TNF inhibitor (MYSTI), a bispecific mini-antibody targeting F4/80 and TNF.

Main Results:

• Demonstrated that TNF from myeloid cells is pathogenic, while TNF from T cells has protective functions.
• MYSTI effectively retained TNF on myeloid cells in vitro and protected mice from TNF-induced hepatotoxicity in vivo.
• MYSTI showed efficacy in experimental arthritis models.

Conclusions:

• Selective inhibition of pathogenic TNF, as achieved by MYSTI, may offer a more effective treatment for autoimmune diseases than broad anti-cytokine therapies.
• Bispecific agents like MYSTI represent promising tools for research and future drug development in autoimmune disorders.